168 related articles for article (PubMed ID: 10386541)
1. Prostate detection possibility.
Gunby P
JAMA; 1999 Jun 23-30; 281(24):2274-5. PubMed ID: 10386541
[No Abstract] [Full Text] [Related]
2. Prostate-specific antigen or human kallikrein 3? Recent developments.
Diamandis EP
Tumour Biol; 1998; 19(2):65-7; discussion 67-8. PubMed ID: 9486557
[No Abstract] [Full Text] [Related]
3. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
[No Abstract] [Full Text] [Related]
4. Diagnostic challenges of clonal heterogeneity in prostate cancer.
Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
[No Abstract] [Full Text] [Related]
5. Prostate Health Index (PHI): golden bullet or just another prostate cancer marker?
Loeb S
Eur Urol; 2013 Jun; 63(6):995-6; discussion 996-7. PubMed ID: 23453055
[No Abstract] [Full Text] [Related]
6. Re: The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-Specific Antigen Levels: A Meta-Analysis.
Siegel C
J Urol; 2015 Aug; 194(2):395. PubMed ID: 26195367
[No Abstract] [Full Text] [Related]
7. Prostate-specific antigen and other prostate cancer markers.
Stenman U; Finne P; Zhang W; Leinonen J
Urology; 2000 Dec; 56(6):893-8. PubMed ID: 11113726
[No Abstract] [Full Text] [Related]
8. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
9. [PSA and blood test diagnostics of prostate cancer].
Seikkula H; Pettersson K; Boström PJ
Duodecim; 2015; 131(17):1547-52. PubMed ID: 26548101
[TBL] [Abstract][Full Text] [Related]
10. Age-specific reference ranges for prostate-specific antigen.
Nooter RI; Bangma CH; Schoder FH
JAMA; 1994 Mar; 271(10):746-7. PubMed ID: 7509418
[No Abstract] [Full Text] [Related]
11. Editorial comment.
Ploussard G
J Urol; 2014 Mar; 191(3):637. PubMed ID: 24291165
[No Abstract] [Full Text] [Related]
12. Re: Kim et al.: detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/ml (Urology 2010;76:919-922).
Shenoy SP; Marla PK; Adappa KK
Urology; 2011 Apr; 77(4):1013-4; author reply 1014. PubMed ID: 21477737
[No Abstract] [Full Text] [Related]
13. Mostly for men.
Isaacson RJ
Angle Orthod; 2005 Jul; 75(4):694. PubMed ID: 16097243
[No Abstract] [Full Text] [Related]
14. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Taneja SS
J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
[No Abstract] [Full Text] [Related]
15. Extremely high PSA (250ng/ml) in a patient with localised prostatic carcinoma.
Colgan G; O'Brien MF; Ahmad I; Thornhill JA
Ir Med J; 2005 Jan; 98(1):29. PubMed ID: 15782735
[No Abstract] [Full Text] [Related]
16. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
17. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups.
Vickers AJ; Vertosick EA; Sjoberg DD
Eur Urol; 2018 Oct; 74(4):535-536. PubMed ID: 29903434
[No Abstract] [Full Text] [Related]
18. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
McDonald ML; Parsons JK
Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
[TBL] [Abstract][Full Text] [Related]
19. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
Loeb S
BJU Int; 2015 Apr; 115(4):500. PubMed ID: 25808708
[No Abstract] [Full Text] [Related]
20. [Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue].
Rabien A; Kristiansen G; Diamandis EP; Jung K; Stephan C
Urologe A; 2007 Sep; 46(9):1070-1. PubMed ID: 17605120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
